The/DT amount/NN of/IN blood/NN 0/-NONE- surgical/JJ patients/NNS can/MD donate/VB and/CC store/VB *T*-1/-NONE- before/IN surgery/NN can/MD be/VB increased/VBN *-3/-NONE- by/IN the/DT new/JJ genetically/RB engineered/VBN drug/NN ,/, EPO/NNP ./.
EPO/NNP ,/, or/CC erythropoietin/NN ,/, is/VBZ a/DT protein/NN 0/-NONE- the/DT human/JJ body/NN makes/VBZ *T*-1/-NONE- *-2/-NONE- to/TO stimulate/VB the/DT growth/NN of/IN red/JJ blood/NN cells/NNS ./.
A/DT genetically/RB engineered/VBN version/NN of/IN the/DT human/JJ protein/NN developed/VBN */-NONE- by/IN Amgen/NNP Corp./NNP of/IN Thousand/NNP Oaks/NNP ,/, Calif./NNP ,/, recently/RB has/VBZ been/VBN marketed/VBN *-1/-NONE- by/IN the/DT Ortho/NNP Pharmaceuticals/NNP division/NN of/IN Johnson/NNP &/CC Johnson/NNP ./.
A/DT competing/VBG version/NN of/IN EPO/NNP is/VBZ being/VBG developed/VBN *-1/-NONE- by/IN Genetics/NNP Institute/NNP Inc./NNP in/IN Cambridge/NNP ,/, Mass/NNP ./.
The/DT drug/NN is/VBZ being/VBG used/VBN *-1/-NONE- primarily/RB */-NONE- to/TO treat/VB anemias/NNS ./.
A/DT new/JJ experiment/NN ,/, reported/VBN */-NONE- in/IN this/DT week/NN 's/POS New/NNP England/NNP Journal/NNP of/IN Medicine/NNP ,/, involved/VBD */-NONE- giving/VBG injections/NNS of/IN Amgen/NNP 's/POS EPO/NNP to/TO 23/CD patients/NNS who/WP *T*-1/-NONE- wanted/VBD *-2/-NONE- to/TO store/VB units/NNS of/IN their/PRP$ own/JJ blood/NN ./.
The/DT patients/NNS began/VBD *-1/-NONE- receiving/VBG EPO/NNP injections/NNS about/IN a/DT month/NN before/IN their/PRP$ scheduled/VBN surgery/NN ./.
They/PRP then/RB began/VBD *-1/-NONE- donating/VBG blood/NN twice/RB a/DT week/NN ,/, *-2/-NONE- receiving/VBG an/DT EPO/NNP injection/NN each/DT time/NN ./.
If/IN tests/NNS indicated/VBD a/DT low/JJ number/NN of/IN red/JJ cells/NNS ,/, blood/NN was/VBD n't/RB taken/VBN *-1/-NONE- ./.
The/DT EPO-treated/JJ patients/NNS donated/VBD an/DT average/NN of/IN 5.4/CD units/NNS of/IN blood/NN each/DT compared/VBN with/IN only/RB 4.1/CD units/NNS donated/VBN */-NONE- by/IN a/DT similar/JJ group/NN of/IN surgical/JJ patients/NNS who/WP *T*-1/-NONE- received/VBD a/DT placebo/NN injection/NN ./.
The/DT volume/NN of/IN red/JJ cells/NNS donated/VBN */-NONE- by/IN the/DT EPO-treated/JJ patients/NNS was/VBD 41/CD %/NN higher/JJR per/IN donor/NN ,/, the/DT research/NN team/NN representing/VBG a/DT number/NN of/IN hospitals/NNS and/CC blood/NN banks/NNS reported/VBD 0/-NONE- *T*-1/-NONE- ./.

